Investors & Media
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Investor Opportunities
Contact UsLatest News
퍼스트바이오, AACR 2026서 HPK1 저해제 ‘FB849’ 항암 면역 활성화 기전 공개
April 1, 2026
2026년 제1회 임시주주총회 소집공고
March 13, 2026
퍼스트바이오·디앤디파마텍, ‘NLY02’ 유럽 특허 확보
March 11, 2026
면역항암제 ‘FB849’ 국내 임상 1/2상 승인
February 10, 2026
퍼스트바이오, 317억 원 규모 시리즈D 투자 유치 완료
January 26, 2026
신주발행공고
January 7, 2026
신주발행공고
December 11, 2025
신주발행공고
December 2, 2025
신주발행공고
December 2, 2025
신주 발행 공고
November 3, 2025
